EcoDrugPlus

Sodium Channel, Voltage-Gated, Type Vii, Alpha

Ensembl ID : ENSMSIG00000013300
Gene Symbol: SCN7A
1 Cross references
101 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Viii, Alpha

Ensembl ID : ENSMSIG00000021532
Gene Symbol: SCN8A
1 Cross references
289 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type X, Alpha

Ensembl ID : ENSMSIG00000002952
Gene Symbol: SCN10A
1 Cross references
312 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Xi, Alpha

Ensembl ID : ENSMSIG00000002716
Gene Symbol: SCN11A
1 Cross references
111 Possible Orthologues:

Solute Carrier Family 18 (Vesicular Monoamine), Member 2

Ensembl ID : ENSMSIG00000028291
Gene Symbol: SLC18A2
1 Cross references
238 Possible Orthologues:

Solute Carrier Family 22 (Organic Anion Transporter), Member 6

Ensembl ID : ENSMSIG00000031188
Gene Symbol: SLC22A6
1 Cross references
505 Possible Orthologues:

Solute Carrier Family 22 (Organic Anion Transporter), Member 8

Ensembl ID : ENSMSIG00000031186
Gene Symbol: SLC22A8
1 Cross references
325 Possible Orthologues:

Solute Carrier Family 22 (Organic Anion/cation Transporter), Member 12

Ensembl ID : ENSMSIG00000029959
Gene Symbol: SLC22A12
1 Cross references
485 Possible Orthologues:

Solute Carrier Family 29 (Nucleoside Transporters), Member 1

Ensembl ID : ENSMSIG00000023420
Gene Symbol: SLC29A1
1 Cross references
299 Possible Orthologues:

Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 1

Ensembl ID : ENSMSIG00000020102
Gene Symbol: SLC5A1
1 Cross references
265 Possible Orthologues:

Solute Carrier Family 5 (Sodium/glucose Cotransporter), Member 2

Ensembl ID : ENSMSIG00000024106
Gene Symbol: SLC5A2
1 Cross references
212 Possible Orthologues:

Solute Carrier Family 6 (Neurotransmitter Transporter, Gaba), Member 1

Ensembl ID : ENSMSIG00000024312
Gene Symbol: SLC6A1
1 Cross references
291 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).